@article{3906,
  keywords = {AI drug discovery, AI drug in clinical trials, AI-discovered drug, AI-native Biotech, Clinical trial success rate},
  author = {Madura KP Jayatunga and Margaret Ayers and Lotte Bruens and Dhruv Jayanth and Christoph Meier},
  title = {How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons},
  abstract = {AI techniques are making inroads into the field of drug discovery. As a result, a growing number of drugs and vaccines have been discovered using AI. However, questions remain about the success of these molecules in clinical trials. To address these questions, we conducted a first analysis of the clinical pipelines of AI-native Biotech companies. In Phase I we find AI-discovered molecules have an 80–90% success rate, substantially higher than historic industry averages. This suggests, we argue, that AI is highly capable of designing or identifying molecules with drug-like properties. In Phase II the success rate is ∼40%, albeit on a limited sample size, comparable to historic industry averages. Our findings highlight early signs of the clinical potential of AI-discovered molecules.},
  year = {2024},
  journal = {Drug Discovery Today},
  volume = {29},
  pages = {104009},
  month = {2024-06-01},
  issn = {1359-6446},
  url = {https://www.sciencedirect.com/science/article/pii/S135964462400134X},
  doi = {10.1016/j.drudis.2024.104009},
}